PT935417E - Formulações entéricas de composições poliméricas antidiarreicas de proantocianidina - Google Patents

Formulações entéricas de composições poliméricas antidiarreicas de proantocianidina Download PDF

Info

Publication number
PT935417E
PT935417E PT97912779T PT97912779T PT935417E PT 935417 E PT935417 E PT 935417E PT 97912779 T PT97912779 T PT 97912779T PT 97912779 T PT97912779 T PT 97912779T PT 935417 E PT935417 E PT 935417E
Authority
PT
Portugal
Prior art keywords
proanthocyanidin polymer
polymer composition
formulations
stomach acid
enteric formulations
Prior art date
Application number
PT97912779T
Other languages
English (en)
Inventor
Edward J Rozhon
Atul S Khandwala
Akram Sabouni
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of PT935417E publication Critical patent/PT935417E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97912779T 1996-10-16 1997-10-14 Formulações entéricas de composições poliméricas antidiarreicas de proantocianidina PT935417E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73077296A 1996-10-16 1996-10-16

Publications (1)

Publication Number Publication Date
PT935417E true PT935417E (pt) 2009-07-17

Family

ID=24936755

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97912779T PT935417E (pt) 1996-10-16 1997-10-14 Formulações entéricas de composições poliméricas antidiarreicas de proantocianidina

Country Status (14)

Country Link
US (5) US7341744B1 (pt)
EP (3) EP0935417B1 (pt)
JP (1) JP4195728B2 (pt)
KR (1) KR100467532B1 (pt)
AT (1) ATE430477T1 (pt)
AU (1) AU4988197A (pt)
CA (1) CA2269078C (pt)
DE (1) DE69739394D1 (pt)
DK (1) DK0935417T3 (pt)
ES (1) ES2326933T3 (pt)
NZ (1) NZ335317A (pt)
PT (1) PT935417E (pt)
TW (1) TW537898B (pt)
WO (1) WO1998016111A1 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430477T1 (de) * 1996-10-16 2009-05-15 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
KR20010108193A (ko) * 1999-02-15 2001-12-07 마사토시 노다 활성성분으로서 프로안토시아니딘을 함유하는에이디피-리보실화 억제제 및 엔테로톡신 타입 세균감염성질환 치료용 조성물
DE60026295T2 (de) * 1999-05-17 2006-10-12 D.B.F. Pflanzenmaterial enthaltendes granulat und verfahren zur herstellung
AU2002241307B9 (en) * 2001-03-28 2005-08-11 Asahi Group Holdings, Ltd. Proteotoxin neutralizer
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
JP5171038B2 (ja) 2003-10-10 2013-03-27 エティファルム イチョウ・エキスを含む放出持続性の微小顆粒およびそのような顆粒の製造方法
KR100720817B1 (ko) * 2003-12-26 2007-05-21 (주)아모레퍼시픽 식물 추출물을 함유하는 제제 및 그 제조방법
JP2006232752A (ja) * 2005-02-25 2006-09-07 Tokyo Univ Of Marine Science & Technology コレステロール及び中性脂肪吸収抑制剤及びこれを含む食品
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20090076132A1 (en) * 2005-03-11 2009-03-19 Gary Pekoe Antiviral compositions and methods of treatment
JP5167461B2 (ja) * 2005-09-16 2013-03-21 国立医薬品食品衛生研究所長 炎症性腸疾患予防剤
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
CA2650022C (en) * 2006-05-01 2017-05-16 Barry Quart Method for treatment of constipation-predominant irritable bowel syndrome
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
EP2061327B1 (en) 2006-05-01 2016-10-05 Napo Pharmaceuticals, Inc. Compositions for treating or preventing inflammatory bowel disease
US8048413B2 (en) * 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
WO2008083513A1 (fr) * 2006-12-13 2008-07-17 Beijing Gingko-Group Biological Technology Co., Ltd. Extrait de pellicule de soja noir et procédé de préparation et d'utilisation de cet extrait
WO2008115605A1 (en) * 2007-03-22 2008-09-25 Ibix Clear bismuth treatments and methods for making
US20110038917A1 (en) * 2007-05-08 2011-02-17 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
EP2252601B1 (en) * 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
FR2938430B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Granules a base de plantes
JP2012519690A (ja) * 2009-03-04 2012-08-30 メタアクティブ、インコーポレイテッド 生体分子の部位活性化複合体形成方法及び材料
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011024049A2 (en) * 2009-08-26 2011-03-03 Glenmark Pharmaceuticals Ltd Method for producing proanthocyanidin polymer compositions for pharmaceutical formulations
US8652534B2 (en) 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2816416C (en) 2010-10-31 2020-02-11 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
BR112013018688B1 (pt) 2011-01-27 2021-08-24 Napo Pharmaceuticals, Inc Método de produção de uma composição polimérica de proantocianidina
JP2014509656A (ja) * 2011-04-01 2014-04-21 オーシャン スプレー クランベリーズ インコーポレイテッド 炎症および免疫の治療
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
AU2013233930A1 (en) * 2012-03-13 2014-09-25 Piramal Enterprises Limited Herbal composition for the treatment of metabolic disorders
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
ITMI20130476A1 (it) 2013-03-28 2014-09-29 Novintethical Pharma Sagl Composizioni per il trattamento di disturbi gastro-intestinali a base di complessi di tannini con proteine
CN103536583B (zh) * 2013-11-01 2015-02-25 潍坊医学院 一种原花青素缓释纳米微球及制备方法和应用
US9938298B2 (en) 2014-05-12 2018-04-10 Alfa Wassermann S.P.A. Solvated crystal form of rifaximin, production, compositions and uses thereof
WO2015184101A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in neonatal and young non-human animals
US20170119834A1 (en) * 2014-05-29 2017-05-04 Jaguar Animal Health, Inc. Methods of Treating Diarrhea in Adult Non-Human Animals
US20170095442A1 (en) * 2014-05-29 2017-04-06 Jaguar Animal Health, Inc. Methods of Treating Salmonella-Induced Diarrhea in Non-Human Animals
CA2972996A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
WO2016138118A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals
US20180028490A1 (en) * 2015-02-26 2018-02-01 Jaguar Health, Inc. Methods Of Treating Diarrhea And Promoting Intestinal Health In Non-Human Animals
WO2018022475A1 (en) * 2016-07-25 2018-02-01 Jaguar Health, Inc Methods of treating porcine epidemic diarrheal virus in piglets
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
US20180168196A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate bacteria in a companion animal
JOP20190275A1 (ar) * 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
US20210361698A1 (en) * 2017-12-27 2021-11-25 Suntory Holdings Limited Composition for improving intestinal barrier function
KR20200008826A (ko) 2018-07-17 2020-01-29 성균관대학교산학협력단 대장균을 이용한 단백질가수분해효소 k의 생산 방법
CN109464491B (zh) * 2018-12-03 2022-02-01 四川省畜牧科学研究院 诃子组合物及其在制备预防和/或治疗腹泻和/或乳房炎的产品中的应用
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377201A1 (fr) * 1977-01-18 1978-08-11 Fabre Sa Pierre Composition pharmaceutique a activite anti-inflammatoire et vasculotrope
SE446940B (sv) * 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
DE3564370D1 (en) * 1985-08-30 1988-09-22 Nestle Sa Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5141735A (en) * 1990-06-18 1992-08-25 Hoffman-La Roche, Inc. Substituted amino-benzodiazepines having anitviral activity
US5211944A (en) * 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
US5750496A (en) * 1996-08-12 1998-05-12 Utah State University Method of controlling cryptosporidium infectons using protease inhibitors
ATE430477T1 (de) 1996-10-16 2009-05-15 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe

Also Published As

Publication number Publication date
TW537898B (en) 2003-06-21
ATE430477T1 (de) 2009-05-15
DK0935417T3 (da) 2009-08-10
US20140011869A1 (en) 2014-01-09
JP4195728B2 (ja) 2008-12-10
EP0935417B1 (en) 2009-05-06
KR20000049206A (ko) 2000-07-25
US20090148397A1 (en) 2009-06-11
KR100467532B1 (ko) 2005-01-24
US20140329896A1 (en) 2014-11-06
EP2060183A2 (en) 2009-05-20
EP2255661A2 (en) 2010-12-01
US7341744B1 (en) 2008-03-11
ES2326933T3 (es) 2009-10-21
US7323195B2 (en) 2008-01-29
EP2060183A3 (en) 2009-06-03
EP0935417A4 (en) 2006-08-30
AU4988197A (en) 1998-05-11
CA2269078A1 (en) 1998-04-23
US20050019389A1 (en) 2005-01-27
DE69739394D1 (de) 2009-06-18
NZ335317A (en) 2001-02-23
JP2001524938A (ja) 2001-12-04
WO1998016111A1 (en) 1998-04-23
EP0935417A1 (en) 1999-08-18
US8574634B2 (en) 2013-11-05
EP2255661A3 (en) 2010-12-22
CA2269078C (en) 2012-01-24

Similar Documents

Publication Publication Date Title
EP0935417A4 (en) ENTERAL FORMULATIONS OF PROANTHOCYANIDE COMPOSITIONS AGAINST DIARRHOE
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
HK1009243A1 (en) Phosphate-binding polymers for oral administration
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
PT1479385E (pt) Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias
AU7535798A (en) Novel cyclosporin derivatives, preparation and pharmaceutical compositions containing same
HUT76330A (en) Antithrombotic peptide-derivates and pharmaceutical compositions comprising them
AU1974692A (en) Oral-administration forms of a medicament containing pantoprazol
CA2160107A1 (en) Compositions for Imparting an Artificial Tan and Protecting the Skin from UV Radiation
CA2214090A1 (en) Oral compositions
HUP0201409A3 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
CA2271623A1 (en) Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth
AU1857888A (en) Reduced base-content chewing gum compositions having anesthetic properties
AU634833B2 (en) Pharmaceutical compositions for treating gastrointestinal distress
EP0693285A3 (en) Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss
UA72909C2 (en) Cinnamide derivatives useful in the treatment of inflammatory and immune diseases, a composition containing such derivatives and a method for the preparation of cinnamide derivatives
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU2001242876A1 (en) Compositions suitable for the treatment of damage caused by ischemia/reperfusionor oxidative stress
PH31395A (en) Bis-naphthalimides for the treatment of cancer.
EP0104768A3 (en) Oral compositions comprising ng-acyl derivatives of arginine
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
CA2095352A1 (en) Compositions containing psyllium
LT96093A (en) The active ingredient of pharmaceutical composition for treating aphtae and stomatitis
CA2330424A1 (en) Improved method for eradication of helicobacter pylori
HK1023516A1 (en) Pharmaceutical composition containing stimulators of interferon-gamma